- Positive Results From Phase 2 Study of Once-weekly FluidCrystal® Formulation of Setmelanotide in Healthy Volunteers With Obesity
- Camurus Raises Full Year 2020 Revenue Guidance
- Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the US
- Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid Dependence
- Camurus' Interim Report January-March 2020
As of last trade
Camurus AB (7CA:BER) traded at 14.80, -2.37% below its 52-week high of 15.16, set on Jul 02, 2020.
5.48Mar 19 202015.16Jul 02 2020
Markit short selling activity
|Market cap||8.18bn SEK|
|EPS (TTM)||-5.73 |
Data delayed at least 15 minutes, as of Jul 08 2020 07:34 BST.